PMC:7172841 / 9861-10413 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T98","span":{"begin":35,"end":54},"obj":"Disease"},{"id":"T99","span":{"begin":101,"end":109},"obj":"Disease"},{"id":"T100","span":{"begin":249,"end":257},"obj":"Disease"},{"id":"T101","span":{"begin":388,"end":396},"obj":"Disease"},{"id":"T102","span":{"begin":401,"end":404},"obj":"Disease"}],"attributes":[{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A101","pred":"mondo_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A102","pred":"mondo_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"}],"text":"Table 2 Association between Severe Respiratory Failure and Immune Classification among Patients with COVID-19 and Patients with Sepsis Caused by Bacterial CAP\nNumber of patients with SRF/total patients [%, (−95% CI, +95% CI)] p value∗\nBacterial CAP COVID-19\nIntermediate 21/40 [52.5 (27.5-67.1)] 0/26 [0 (0-12.9)] \u003c0.0001\nImmunoparalysis (for bacterial CAP) and immune dysregulation (for COVID-19) or MAS 35/64 [54.7 (42.6-66.3)] 28/28 [100 (87.9-100)] \u003c0.0001\n∗comparisons by the Fisher exact test. Abbreviation is as follows: CI, confidence interval."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T60","span":{"begin":405,"end":407},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T61","span":{"begin":494,"end":498},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Table 2 Association between Severe Respiratory Failure and Immune Classification among Patients with COVID-19 and Patients with Sepsis Caused by Bacterial CAP\nNumber of patients with SRF/total patients [%, (−95% CI, +95% CI)] p value∗\nBacterial CAP COVID-19\nIntermediate 21/40 [52.5 (27.5-67.1)] 0/26 [0 (0-12.9)] \u003c0.0001\nImmunoparalysis (for bacterial CAP) and immune dysregulation (for COVID-19) or MAS 35/64 [54.7 (42.6-66.3)] 28/28 [100 (87.9-100)] \u003c0.0001\n∗comparisons by the Fisher exact test. Abbreviation is as follows: CI, confidence interval."}

{"project":"LitCovid-sentences","denotations":[{"id":"T78","span":{"begin":0,"end":158},"obj":"Sentence"},{"id":"T79","span":{"begin":159,"end":234},"obj":"Sentence"},{"id":"T80","span":{"begin":235,"end":257},"obj":"Sentence"},{"id":"T81","span":{"begin":258,"end":321},"obj":"Sentence"},{"id":"T82","span":{"begin":322,"end":460},"obj":"Sentence"},{"id":"T83","span":{"begin":461,"end":499},"obj":"Sentence"},{"id":"T84","span":{"begin":500,"end":552},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 2 Association between Severe Respiratory Failure and Immune Classification among Patients with COVID-19 and Patients with Sepsis Caused by Bacterial CAP\nNumber of patients with SRF/total patients [%, (−95% CI, +95% CI)] p value∗\nBacterial CAP COVID-19\nIntermediate 21/40 [52.5 (27.5-67.1)] 0/26 [0 (0-12.9)] \u003c0.0001\nImmunoparalysis (for bacterial CAP) and immune dysregulation (for COVID-19) or MAS 35/64 [54.7 (42.6-66.3)] 28/28 [100 (87.9-100)] \u003c0.0001\n∗comparisons by the Fisher exact test. Abbreviation is as follows: CI, confidence interval."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T45","span":{"begin":35,"end":54},"obj":"Phenotype"},{"id":"T46","span":{"begin":128,"end":134},"obj":"Phenotype"},{"id":"T47","span":{"begin":362,"end":382},"obj":"Phenotype"}],"attributes":[{"id":"A45","pred":"hp_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A46","pred":"hp_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/HP_0100806"},{"id":"A47","pred":"hp_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"Table 2 Association between Severe Respiratory Failure and Immune Classification among Patients with COVID-19 and Patients with Sepsis Caused by Bacterial CAP\nNumber of patients with SRF/total patients [%, (−95% CI, +95% CI)] p value∗\nBacterial CAP COVID-19\nIntermediate 21/40 [52.5 (27.5-67.1)] 0/26 [0 (0-12.9)] \u003c0.0001\nImmunoparalysis (for bacterial CAP) and immune dysregulation (for COVID-19) or MAS 35/64 [54.7 (42.6-66.3)] 28/28 [100 (87.9-100)] \u003c0.0001\n∗comparisons by the Fisher exact test. Abbreviation is as follows: CI, confidence interval."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T182","span":{"begin":101,"end":109},"obj":"SP_7"},{"id":"T43119","span":{"begin":9,"end":11},"obj":"PR:000001092"},{"id":"T6790","span":{"begin":11,"end":12},"obj":"PR:000001092;GO:1990774"},{"id":"T98296","span":{"begin":12,"end":14},"obj":"PR:000001092;GO:0032620"},{"id":"T16142","span":{"begin":71,"end":78},"obj":"NCBITaxon:5478"},{"id":"T99218","span":{"begin":79,"end":87},"obj":"NCBITaxon:8296"},{"id":"T387","span":{"begin":456,"end":466},"obj":"SP_7"},{"id":"T388","span":{"begin":496,"end":499},"obj":"PR:000001004"},{"id":"T389","span":{"begin":500,"end":504},"obj":"PR:000001006"},{"id":"T390","span":{"begin":506,"end":517},"obj":"CL:0000542"},{"id":"T391","span":{"begin":531,"end":535},"obj":"PR:000001006"},{"id":"T392","span":{"begin":537,"end":548},"obj":"CL:0000542"}],"text":"Table 2 Association between Severe Respiratory Failure and Immune Classification among Patients with COVID-19 and Patients with Sepsis Caused by Bacterial CAP\nNumber of patients with SRF/total patients [%, (−95% CI, +95% CI)] p value∗\nBacterial CAP COVID-19\nIntermediate 21/40 [52.5 (27.5-67.1)] 0/26 [0 (0-12.9)] \u003c0.0001\nImmunoparalysis (for bacterial CAP) and immune dysregulation (for COVID-19) or MAS 35/64 [54.7 (42.6-66.3)] 28/28 [100 (87.9-100)] \u003c0.0001\n∗comparisons by the Fisher exact test. Abbreviation is as follows: CI, confidence interval."}

{"project":"LitCovid-PubTator","denotations":[{"id":"330","span":{"begin":169,"end":177},"obj":"Species"},{"id":"331","span":{"begin":193,"end":201},"obj":"Species"},{"id":"332","span":{"begin":183,"end":186},"obj":"Disease"},{"id":"333","span":{"begin":249,"end":257},"obj":"Disease"},{"id":"334","span":{"begin":317,"end":337},"obj":"Disease"},{"id":"335","span":{"begin":388,"end":396},"obj":"Disease"},{"id":"341","span":{"begin":87,"end":95},"obj":"Species"},{"id":"342","span":{"begin":114,"end":122},"obj":"Species"},{"id":"343","span":{"begin":35,"end":54},"obj":"Disease"},{"id":"344","span":{"begin":101,"end":109},"obj":"Disease"},{"id":"345","span":{"begin":128,"end":134},"obj":"Disease"}],"attributes":[{"id":"A330","pred":"tao:has_database_id","subj":"330","obj":"Tax:9606"},{"id":"A331","pred":"tao:has_database_id","subj":"331","obj":"Tax:9606"},{"id":"A333","pred":"tao:has_database_id","subj":"333","obj":"MESH:C000657245"},{"id":"A335","pred":"tao:has_database_id","subj":"335","obj":"MESH:C000657245"},{"id":"A341","pred":"tao:has_database_id","subj":"341","obj":"Tax:9606"},{"id":"A342","pred":"tao:has_database_id","subj":"342","obj":"Tax:9606"},{"id":"A343","pred":"tao:has_database_id","subj":"343","obj":"MESH:D012131"},{"id":"A344","pred":"tao:has_database_id","subj":"344","obj":"MESH:C000657245"},{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"MESH:D018805"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 2 Association between Severe Respiratory Failure and Immune Classification among Patients with COVID-19 and Patients with Sepsis Caused by Bacterial CAP\nNumber of patients with SRF/total patients [%, (−95% CI, +95% CI)] p value∗\nBacterial CAP COVID-19\nIntermediate 21/40 [52.5 (27.5-67.1)] 0/26 [0 (0-12.9)] \u003c0.0001\nImmunoparalysis (for bacterial CAP) and immune dysregulation (for COVID-19) or MAS 35/64 [54.7 (42.6-66.3)] 28/28 [100 (87.9-100)] \u003c0.0001\n∗comparisons by the Fisher exact test. Abbreviation is as follows: CI, confidence interval."}